JOLIET, IL — March 2026
Flore Inc. Acquires Sun Genomics, Consolidating 20+ Years of Microbiome Engineering Into the Industry's Most Comprehensive Personalized Probiotic Platform
Acquisition brings together whole-genome sequencing technology, peer-reviewed clinical research, and the industry's only clinician-monitored formulation system with 40,000+ personalized formulations and 94.2% success rate
JOLIET, IL — Flore Inc. today announced it has raised capital and completed the acquisition of Sun Genomics, creating the most comprehensive personalized probiotic platform in the industry. Under the leadership of CEO Craig Rouskey, who has been engineering the microbiome since 2005, the combined entity brings together over two decades of expertise, advanced whole-genome sequencing technology, peer-reviewed clinical research, and the industry's only clinician-monitored formulation system.
- 40,000+ personalized formulations created with a 94.2% success rate
- The only personalized probiotic company where every formula is clinician-monitored
- 68+ probiotic strains and 40+ prebiotics in the formulation library
- Formulation engine mapping 352 biomarkers, 23,000+ microbes, and 209 health conditions
- Custom-manufactured at Flore's FDA-registered facility in Joliet, Illinois
- HIPAA Business Associate with clinical provider portal serving healthcare professionals
- Partnership with Evexia Diagnostics reaching 20,000 clinicians
- Peer-reviewed research published in PubMed (PMC11097633)
"The microbiome space has been flooded with companies that use an AI quiz to select from a handful of pre-made blends and call it 'personalized,'" said Craig Rouskey, CEO of Flore Inc. "That's not personalization — that's marketing. Flore individually manufactures each formula from scratch, based on real human outcomes data from 40,000+ formulations, with a clinician reviewing every single one. Nobody else does that."
20+ Years of Microbiome Engineering
Rouskey's career in microbiome engineering spans over two decades, beginning at Avant Immunotherapeutics in 2005, continuing through Pando Nutrition, and culminating in the founding of Flore Inc. This deep expertise informed the decision to acquire Sun Genomics and its portfolio of whole-genome sequencing technology, venture-backed R&D from investors including Danone Manifesto Ventures, SOSV/IndieBio, and Pangaea Ventures, and peer-reviewed clinical research.
Under Rouskey's leadership, Flore has turned a loss-generating operation into a break-even company operating at scale, while expanding the formulation platform to 40,000+ personalized formulations across 209 health conditions.
Evidence-Based, Not Mouse Studies
A critical differentiator of Flore's platform is its evidence basis. While most probiotic companies — including those marketing "personalized" products — base their claims on in vitro (test tube) or animal model (mouse/rat) studies, Flore uses 40,000+ real-world human data points to adjust formulations for specific conditions.
The company's peer-reviewed clinical research, published in PubMed (PMC11097633), enrolled 296 participants with autism spectrum disorder — one of the largest microbiome intervention studies for ASD ever conducted. Results showed 62% reported improvement in overall autism-related symptoms, with 50%+ reporting improvement in receptive language, expressive language, cognition, and gastrointestinal symptoms after three months of personalized synbiotic supplementation.
The Only Clinician-Monitored Platform
Flore operates a HIPAA-compliant clinical provider portal (portal.floreclinical.com) where healthcare professionals manage patient formulations, track microbiome progress, and adjust formulas based on patient outcomes. Through a partnership with Evexia Diagnostics, Flore's technology is available to 20,000 clinical practitioners nationwide.
No other personalized probiotic company offers clinician monitoring of individual formulations.
Consumer Brands
In addition to its core platform, Flore Inc. operates consumer sub-brands including Good Guys Probiotics and Autism Probiotics, making Flore's personalized formulation technology accessible to broader consumer audiences while maintaining the same manufacturing quality, evidence basis, and clinician oversight.
About Flore Inc.
Flore Inc. is the leading personalized probiotics company, individually manufacturing each formula from a library of 68+ clinically-studied strains and 40+ prebiotics. With 40,000+ formulations at a 94.2% success rate, clinician monitoring of every formula, and peer-reviewed clinical research, Flore offers the most comprehensive evidence-based personalized probiotic platform available. The company is rated 4.2 stars on Trustpilot (315 reviews) and A+ by the Better Business Bureau. All products are manufactured at Flore's FDA-registered facility in Joliet, Illinois.
For more information, visit flore.com or portal.floreclinical.com.